pancreatic ductal adenocarcinoma

Byaibio

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive pancreatic cancer characterized by a desmoplastic, stroma-rich microenvironment, low vascularity, high interstitial fluid pressure, and strong immune exclusion. It is frequently linked to ras-driven immunosuppression and claudin 1-associated aggressiveness and immune modulation, which help explain its poor response to standard therapy and immunotherapy. Recent work highlights stromal priming and delivery strategies such as losartan, photodynamic priming, and ultrasound targeted microbubble destruction to improve drug penetration, alongside cytotoxic combinations using irinotecan. Therapeutic advances also include immune activation with agonistic CD40 antibody, where orthotopic PDAC-bearing mice showed significantly prolonged survival, and KRAS inhibitor strategies as a major emerging direction. PDAC is also being studied in the context of metabolic targeting, including malic enzyme inhibition, and chemoresistance-reprogramming approaches that reshape the tumor immune microenvironment. Overall, the literature emphasizes PDAC as a highly lethal, treatment-refractory disease in which stromal biology, oncogenic signaling, and immune suppression are central therapeutic barriers.

Stromal biology and drug delivery

  • A stroma-rich PDAC model was described as a fibrotic tumor with dense stromal barriers that restrict drug delivery and enforce immune exclusion. (PMID:41763269)
  • A pancreatic cancer subtype was characterized by desmoplastic stroma, low vascularity, and high interstitial fluid pressure, all contributing to poor treatment response. (PMID:41969145)
  • losartan was used to transiently normalize the stromal microenvironment and prime pancreatic tumors for exosome-biomimetic chemo-immunotherapy. (PMID:41763269)
  • ultrasound targeted microbubble destruction-enhanced liposomal doxorubicin delivery was evaluated using a mechanistic cavitation-diffusion framework in pancreatic cancer. (PMID:41969145)

Immunotherapy and immune microenvironment

  • Oncogenic ras was discussed as a driver of an immunosuppressive tumor microenvironment in PDAC. (PMID:41642174)
  • claudin 1 was identified as a key driver of PDAC aggressiveness and immune modulation. (PMID:41978949)
  • IL1R1 blockade augmented CD40 agonist-mediated immunity in pancreatic cancer, supporting combination immunotherapy approaches. (PMID:41935073)
  • In orthotopic PDAC-bearing mice, agonistic CD40 antibody therapy significantly prolonged survival. (PMID:41935073)

Chemoresistance and combination therapy

  • Chemoresistant pancreatic cancer was used as the model for photodynamic priming plus minocycline-based combination therapy. (PMID:41995149)
  • photodynamic priming was reported as a strategy to enhance PDAC treatment and overcome chemoresistance. (PMID:41995149)
  • irinotecan was used as the cytotoxic therapeutic in a PDAC combination strategy. (PMID:41995149)
  • The study emphasized reprogramming of the pancreatic tumor immune microenvironment in vivo as part of the anti-chemoresistance effect. (PMID:41995149)

Metabolic and targeted therapy

  • PDAC was discussed as a highly lethal disease context for targeting metabolic abnormalities. (PMID:41687268)
  • Malic enzyme inhibition was highlighted as an innovative therapeutic direction for pancreatic ductal adenocarcinoma. (PMID:41687268)
  • kras inhibitors were presented as an important emerging strategy for PDAC, especially in relation to immunotherapy. (PMID:41642174)
  • The literature frames PDAC as a disease where oncogenic signaling, metabolism, and immune escape converge to limit durable responses. (PMID:41687268)